Pharmacovigilance Market Size By Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III, Phase IV), By Service Provider (In-house, Contract Outsourcing), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 - 2025


Pharmacovigilance market is expected to exceed USD 8.9 billion by 2025. The increasing drug consumption and growing concerns regarding adverse drug effects across the globe will drive market growth over the analysis timeframe.

Some major findings of the pharmacovigilance market report include:
      - 	Growing adoption of personalized medicines and increasing demand for targeted drugs will drive the demand for pharmacovigilance services

      - 	Need of pharmacovigilance for effective surveillance of adverse drug reactions will render several growth opportunities 

      - 	Contract outsourcing segment to witness significant growth owing to reduced operational costs, efficient monitoring through regulatory compliance, enhanced productivity and higher quality provided by outsourcing companies

      - 	Industry players operating in the pharmacovigilance market such as Cognizant, TCS, Accenture, IQVIA and ICON among others, adopt various organic and inorganic growth strategies to capitalize on market opportunities 

Growing prevalence of chronic diseases, increasing accessibility to drugs and rising per capita healthcare expenditure in various countries across the globe will serve to be major impact rendering factors for the pharmacovigilance industry growth. The consumption of drugs is increasing day by day, wherein, a large proportion of prescription drugs is abused. According to the Centers for Disease Control and Prevention, in 2017, over 28,000 deaths occurred due to consumption of synthetic opioids in the U.S. Increasing drug consumption and concerns regarding adverse drug reactions will surge the demand for pharmacovigilance activities in the coming years. 

Moreover, adoption of personalized medicines is growing considerably, especially in the developed nations. Growing adoption of gene therapy in the treatment of different types of cancer and other chronic diseases, will surge the demand for personalized medicines over the forecast period. Advances in personalized and precision medicine are anticipated to offer highly specific solutions to individuals by considering their genetic composition and its reactions to medicine. Innovations in personalized medicine and its growing acceptance will escalate the need for pharmacovigilance practices.

The clinical trial phases segment is divided into preclinical studies, phase I, phase II, phase III and phase IV. Phase IV pharmacovigilance segment held significant revenue share of more than 70% in 2018. Pharmacovigilance is vital for safety surveillance after the drug is released in the market. It detects and reports any adverse drug reactions (ADRs) & harmful effects that may result into discontinuation of drugs or may be limited for use in certain patients. Thus, increasing number of pharmaceutical companies focusing on new drug development will positively impact the business growth.

The service providers segment is bifurcated into in-house and contract outsourcing. In-house services segment held around 45% revenue share in 2018 and is estimated to grow considerably over the forecast timeframe. Concerns regarding data safety and confidentiality will increase the preference towards in-house pharmacovigilance services. Moreover, presence of companies with skilled staff and developed infrastructure will further favor segmental growth. However, less cost-effectivity and dearth of expertise can be a potential challenge that may impede segmental growth in certain developing and underdeveloped countries.

Europe pharmacovigilance market is projected to experience over 9.5% CAGR during the analysis period. High centralization and harmonization of pharmacovigilance practices will lead to more effective detection of safety signals in the Europe. New regulations for pharmacovigilance imposed in the European Union (EU) since July 2012, has led to increased involvement of healthcare professionals and patients in the Pharmacovigilance and Risk Assessment Committee (PRAC). Moreover, evolution in personalized medicines will offer ample opportunities for the regional market growth.

Some of the notable industry players operating in the pharmacovigilance market include Accenture, Clinquest Group, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Cognizant, Ecron Acunova Ltd, F. Hoffmann-La Roche Ltd, IQVIA, HCL Technologies, IBM Corporation, ICON and Infosys Ltd. These industry players resort to acquisitions, mergers and new product launch to sustain market positions. For instance, in May 2015, Pfizer introduced Reportum, a pharmacovigilance solution developed by MyMeds&Me, in the U.S. market. Reportum is deployed across all Pfizer safety call centers in the U.S. and helps in collection of data related to adverse events.
Report Content
 
 Chapter 1. Methodology
 
 1.1. Methodology
 
 1.2. Market definitions
 
 1.3. Forecast parameters
 
 1.4. Data sources
 
 1.4.1. Secondary
 
 1.4.1.1. Paid sources
 
 1.4.1.2. Unpaid sources
 
 1.4.2. Primary
 
 Chapter 2. Executive Summary
 
 2.1. Pharmacovigilance industry 360 degree synopsis, 2014 - 2025
 
 2.1.1. Business trends
 
 2.1.2. Clinical trial phase trends
 
 2.1.3. Service provider trends
 
 2.1.4. Regional trends
 
 Chapter 3. Pharmacovigilance Industry Insights
 
 3.1. Industry segmentation
 
 3.2. Industry landscape, 2014 - 2025
 
 3.3. Industry impact forces
 
 3.3.1. Growth drivers
 
 3.3.1.1. Growth in adoption rate of outsourcing services in Asia Pacific
 
 3.3.1.2. Increasing consumption of drugs in developed regions
 
 3.3.1.3. Rise in adverse drug reactions (ADR) and drug toxicity
 
 3.3.1.4. Increasing acceptance of personalized medicine in developed regions
 
 3.3.1.5. Effective global harmonization practices
 
 3.3.2. Industry pitfalls and challenges
 
 3.3.2.1. Dearth of skilled personnel
 
 3.3.2.2. High risk associated with data security
 
 3.4. Growth potential analysis
 
 3.4.1. By clinical trial phase
 
 3.4.2. By service provider
 
 3.5. New business models
 
 3.6. Regulatory landscape
 
 3.7. Pharmacovigilance reporting system
 
 3.8. Porter's analysis
 
 3.9. Competitive landscape, 2018
 
 3.9.1. Strategy dashboard
 
 3.10. PESTEL analysis
 
 Chapter 4. Pharmacovigilance Market, By Clinical Trial Phase
 
 4.1. Key segment trends
 
 4.2. Preclinical
 
 4.2.1. Market size, by region, 2014 - 2025 (USD Million)
 
 4.3. Phase I
 
 4.3.1. Market size, by region, 2014 - 2025 (USD Million)
 
 4.4. Phase II
 
 4.4.1. Market size, by region, 2014 - 2025 (USD Million)
 
 4.5. Phase III
 
 4.5.1. Market size, by region, 2014 - 2025 (USD Million)
 
 4.6. Phase IV
 
 4.6.1. Market size, by region, 2014 - 2025 (USD Million)
 
 Chapter 5. Pharmacovigilance Market, By Service Provider
 
 5.1. Key segment trend
 
 5.2. In-house
 
 5.2.1. Market size, by region, 2014 - 2025 (USD Million)
 
 5.3. Contract resourcing
 
 5.3.1. Market size, by region, 2014 - 2025 (USD Million)
 
 Chapter 6. Pharmacovigilance Market, By Region
 
 6.1. Key regional market
 
 6.2. North America
 
 6.2.1. Market size, by country, 2014 - 2025 (USD Million)
 
 6.2.2. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.2.3. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.2.4. U.S.
 
 6.2.4.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.2.4.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.2.5. Canada
 
 6.2.5.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.2.5.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.3. Europe
 
 6.3.1. Market size, by country, 2014 - 2025 (USD Million)
 
 6.3.2. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.3.3. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.3.4. Germany
 
 6.3.4.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.3.4.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.3.5. UK
 
 6.3.5.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.3.5.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.3.6. Spain
 
 6.3.6.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.3.6.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.3.7. Italy
 
 6.3.7.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.3.7.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.3.8. France
 
 6.3.8.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.3.8.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.4. Asia Pacific
 
 6.4.1. Market size, by country, 2014 - 2025 (USD Million)
 
 6.4.2. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.4.3. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.4.4. Japan
 
 6.4.4.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.4.4.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.4.5. China
 
 6.4.5.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.4.5.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.4.6. India
 
 6.4.6.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.4.6.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.4.7. Australia
 
 6.4.7.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.4.7.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.5. Latin America
 
 6.5.1. Market size, by country, 2014 - 2025 (USD Million)
 
 6.5.2. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.5.3. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.5.4. Argentina
 
 6.5.4.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.5.4.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.5.5. Brazil
 
 6.5.5.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.5.5.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.5.6. Mexico
 
 6.5.6.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.5.6.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.6. MEA
 
 6.6.1. Market size, by country, 2014 - 2025 (USD Million)
 
 6.6.2. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.6.3. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.6.4. South Africa
 
 6.6.4.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.6.4.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.6.5. UAE
 
 6.6.5.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.6.5.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.6.6. Saudi Arabia
 
 6.6.6.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.6.6.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.6.7. Qatar
 
 6.6.7.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.6.7.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 6.6.8. Israel
 
 6.6.8.1. Market size, by clinical trial phase, 2014 - 2025 (USD Million)
 
 6.6.8.2. Market size, by service provider, 2014 - 2025 (USD Million)
 
 Chapter 7. Company Profiles
 
 7.1. Accenture
 
 7.1.1. Business overview
 
 7.1.2. Financial data
 
 7.1.3. Service landscape
 
 7.1.4. Strategic outlook
 
 7.1.5. SWOT analysis
 
 7.2. Boehringer Ingelheim
 
 7.2.1. Business overview
 
 7.2.2. Financial data
 
 7.2.3. Service landscape
 
 7.2.4. Strategic outlook
 
 7.2.5. SWOT analysis
 
 7.3. Bristol-Myers Squibb
 
 7.3.1. Business overview
 
 7.3.2. Financial data
 
 7.3.3. Service landscape
 
 7.3.4. Strategic outlook
 
 7.3.5. SWOT analysis
 
 7.4. Clinquest Group B.V.
 
 7.4.1. Business overview
 
 7.4.2. Financial data
 
 7.4.3. Service landscape
 
 7.4.4. Strategic outlook
 
 7.4.5. SWOT analysis
 
 7.5. Cognizant Technology Solutions Corporation
 
 7.5.1. Business overview
 
 7.5.2. Financial data
 
 7.5.3. Service landscape
 
 7.5.4. Strategic outlook
 
 7.5.5. SWOT analysis
 
 7.6. Ecron Acunova Ltd.
 
 7.6.1. Business overview
 
 7.6.2. Financial data
 
 7.6.3. Service landscape
 
 7.6.4. Strategic outlook
 
 7.6.5. SWOT analysis
 
 7.7. F. Hoffmann-La Roche Ltd.
 
 7.7.1. Business overview
 
 7.7.2. Financial data
 
 7.7.3. Service landscape
 
 7.7.4. Strategic outlook
 
 7.7.5. SWOT analysis
 
 7.8. GlaxoSmithKline
 
 7.8.1. Business overview
 
 7.8.2. Financial data
 
 7.8.3. Service landscape
 
 7.8.4. Strategic outlook
 
 7.8.5. SWOT analysis
 
 7.9. HCL Technologies
 
 7.9.1. Business overview
 
 7.9.2. Financial data
 
 7.9.3. Service landscape
 
 7.9.4. Strategic outlook
 
 7.9.5. SWOT analysis
 
 7.10. IBM Corporation
 
 7.10.1. Business overview
 
 7.10.2. Financial data
 
 7.10.3. Service landscape
 
 7.10.4. Strategic outlook
 
 7.10.5. SWOT analysis
 
 7.11. ICON plc
 
 7.11.1. Business overview
 
 7.11.2. Financial data
 
 7.11.3. Service landscape
 
 7.11.4. Strategic outlook
 
 7.11.5. SWOT analysis
 
 7.12. iGATE Corporation (Capgemini)
 
 7.12.1. Business overview
 
 7.12.2. Financial data
 
 7.12.3. Service landscape
 
 7.12.4. Strategic outlook
 
 7.12.5. SWOT analysis
 
 7.13. Infosys Ltd.
 
 7.13.1. Business overview
 
 7.13.2. Financial data
 
 7.13.3. Service landscape
 
 7.13.4. Strategic outlook
 
 7.13.5. SWOT analysis
 
 7.14. InVentiv Health Clinical
 
 7.14.1. Business overview
 
 7.14.2. Financial data
 
 7.14.3. Service landscape
 
 7.14.4. Strategic outlook
 
 7.14.5. SWOT analysis
 
 7.15. Ipca Laboratories Ltd.
 
 7.15.1. Business overview
 
 7.15.2. Financial data
 
 7.15.3. Service landscape
 
 7.15.4. Strategic outlook
 
 7.15.5. SWOT analysis
 
 7.16. IQVIA (QuintilesIMS)
 
 7.16.1. Business overview
 
 7.16.2. Financial data
 
 7.16.3. Service landscape
 
 7.16.4. Strategic outlook
 
 7.16.5. SWOT analysis
 
 7.17. ITclinical
 
 7.17.1. Business overview
 
 7.17.2. Financial data
 
 7.17.3. Service landscape
 
 7.17.4. Strategic outlook
 
 7.17.5. SWOT analysis
 
 7.18. Janssen Research & Development, LLC
 
 7.18.1. Business overview
 
 7.18.2. Financial data
 
 7.18.3. Service landscape
 
 7.18.4. Strategic outlook
 
 7.18.5. SWOT analysis
 
 7.19. Laboratory Corporation of America Holdings
 
 7.19.1. Business overview
 
 7.19.2. Financial data
 
 7.19.3. Service landscape
 
 7.19.4. Strategic outlook
 
 7.19.5. SWOT analysis
 
 7.20. Novartis AG
 
 7.20.1. Business overview
 
 7.20.2. Financial data
 
 7.20.3. Service landscape
 
 7.20.4. Strategic outlook
 
 7.20.5. SWOT analysis
 
 7.21. Oracle Corporation
 
 7.21.1. Business overview
 
 7.21.2. Financial data
 
 7.21.3. Service landscape
 
 7.21.4. Strategic outlook
 
 7.21.5. SWOT analysis
 
 7.22. PAREXEL International Corporation
 
 7.22.1. Business overview
 
 7.22.2. Financial data
 
 7.22.3. Service landscape
 
 7.22.4. Strategic outlook
 
 7.22.5. SWOT analysis
 
 7.23. Pfizer
 
 7.23.1. Business overview
 
 7.23.2. Financial data
 
 7.23.3. Service landscape
 
 7.23.4. Strategic outlook
 
 7.23.5. SWOT analysis
 
 7.24. Sanofi Aventis
 
 7.24.1. Business overview
 
 7.24.2. Financial data
 
 7.24.3. Service landscape
 
 7.24.4. Strategic outlook
 
 7.24.5. SWOT analysis
 
 7.25. TCS
 
 7.25.1. Business overview
 
 7.25.2. Financial data
 
 7.25.3. Service landscape
 
 7.25.4. Strategic outlook
 
 7.25.5. SWOT analysis
 
 7.26. Wipro
 
 7.26.1. Business overview
 
 7.26.2. Financial data
 
 7.26.3. Service landscape
 
 7.26.4. Strategic outlook
 
 7.26.5. SWOT analysis

Data Tables TABLE 1. Pharmacovigilance industry 360 degree synopsis, 2014 - 2025 TABLE 2. Pharmacovigilance market, 2014-2018 (USD Million) TABLE 3. Pharmacovigilance market, 2019-2025 (USD Million) TABLE 4. Pharmacovigilance market, by clinical trial phase, 2014-2018 (USD Million) TABLE 5. Pharmacovigilance market, by clinical trial phase, 2019-2025 (USD Million) TABLE 6. Pharmacovigilance market, by service provider, 2014-2018 (USD Million) TABLE 7. Pharmacovigilance market, by service provider, 2019-2025 (USD Million) TABLE 8. Pharmacovigilance market, by region, 2014-2018 (USD Million) TABLE 9. Pharmacovigilance market, by region, 2019-2025 (USD Million) TABLE 10. Industry impact forces TABLE 11. Pharmacovigilance regulatory initiatives TABLE 12. Preclinical market size, by region, 2014-2025 (USD Million) TABLE 13. Phase I market size, by region, 2014-2025 (USD Million) TABLE 14. Phase II market size, by region, 2014-2025 (USD Million) TABLE 15. Phase III market size, by region, 2014-2025 (USD Million) TABLE 16. Phase IV market size, by region, 2014-2025 (USD Million) TABLE 17. In-house market size, by region, 2014-2025 (USD Million) TABLE 18. Contract outsourcing market size, by region, 2014-2025 (USD Million) TABLE 19. North America pharmacovigilance market size, by country, 2014-2025 (USD Million) TABLE 20. North America pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 21. North America pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 22. U.S. pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 23. U.S. pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 24. Canada pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 25. Canada pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 26. Europe pharmacovigilance market size, by country, 2014-2025 (USD Million) TABLE 27. Europe pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 28. Europe pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 29. Germany pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 30. Germany pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 31. UK pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 32. UK pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 33. Spain pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 34. Spain pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 35. Italy pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 36. Italy pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 37. France pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 38. France pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 39. Asia Pacific pharmacovigilance market size, by country, 2014-2025 (USD Million) TABLE 40. Asia Pacific pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 41. Asia Pacific pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 42. Japan pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 43. Japan pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 44. China pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 45. China pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 46. India pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 47. India pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 48. Australia pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 49. Australia pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 50. Latin America pharmacovigilance market size, by country, 2014-2025 (USD Million) TABLE 51. Latin America pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 52. Latin America pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 53. Argentina pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 54. Argentina pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 55. Brazil pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 56. Brazil pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 57. Mexico pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 58. Mexico pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 59. MEA pharmacovigilance market size, by country, 2014-2025 (USD Million) TABLE 60. MEA pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 61. MEA pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 62. South Africa pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 63. South Africa pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 64. UAE pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 65. UAE pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 66. Saudi Arabia pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 67. Saudi Arabia pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 68. Qatar pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 69. Qatar pharmacovigilance market size, by service provider, 2014-2025 (USD Million) TABLE 70. Israel pharmacovigilance market size, by clinical trial phase, 2014-2025 (USD Million) TABLE 71. Israel pharmacovigilance market size, by service provider, 2014-2025 (USD Million) Charts & Figures FIG 1. Industry segmentation FIG 2. Global pharmacovigilance market, 2014 - 2025 (USD Million) FIG 3. Growth potential analysis, by clinical trial phase FIG 4. Growth potential analysis, by service provider FIG 5. Types of pharmacovigilance outsourcing vendors FIG 6. Porter's analysis FIG 7. Company market share analysis, 2018 FIG 8. Strategy dashboard FIG 9. PESTEL analysis

Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

New Pharmaceuticals and Healthcare Reports

Internal Neuromodulation Market Forecast 2025 | Global Report

Rising number of patients suffering from neurological disorders such as Parkinson’s, essential tremor, and primary dystonia is fueling the demand for internal neuromodulation procedures. Chronic back and leg pain associated with PVD (peripheral...

Gastrointestinal Cancer Treatment Market Size 2020-2025 | Growth Forecasts

As per credible projections, gastrointestinal cancer treatment industry is expected to register strong CAGR over 2019-2025. Rising adoption of unhealthy eating habits and increasing consumption of tobacco and alcohol have increased the pervasiveness ...

Topotecan Hydrochloride Market Trends and Research Insights by 2025

As per credible estimates, global topotecan hydrochloride market is poised to acquire commendable gains by the year 2025. Rising adoption of unhealthy and sedentary lifestyle has increased the pervasiveness of small cell lung cancer, ovarian cancer, ...

Flu Vaccine Market Share 2020-2025 | Global Industry Report

As per trusted estimates, global flu vaccine market will record substantial growth during 2020-2025. Increasing government initiatives to ensure the safety of the populace, minimal side-effects associated with influenza vaccines, improving efficacy o...

Healthcare Linen Market Size - Industry Trends Report 2025

According to reliable projections, global healthcare linen market is projected to record considerable growth during 2020-2025. Rising prevalence of various diseases including cardiovascular diseases, cancer, and arthritis along with increasing cases ...

Other Reports by Global Market Insights, Inc.

Chilled Beams Market Size By Product (Active, Passive, Multiservice), By Material (Gypsum, Metal, Aluminum, Plastering), By Application (Offices, Retail, Hotel & Leisure, Industrial), By Business (New Construction, Renovation), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026

The chilled beams market is likely to see a remunerative growth trend over the coming years owing to the increasing adoption of multiservice chilled beams systems. A chilled beam is usually an air distribution device with an essential coil which migh...

Structural Composites Market Size By Matrix (Polymer, Wood, Metal), By Reinforcement Materials (Glass Fiber, Carbon Fiber, Aramid Fiber), By Sector (Construction & Infrastructure, Energy, Transportation [Automotive, Aerospace & Defense]), Industry Analysis Report, Regional Outlook, Application Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026

The structural composites market is projected to record momentous gains over the forthcoming timeframe owing to rising construction activities and demand for high strength, lightweight composites for sports goods across the globe. A composite materia...

Smart Weapons Market Size By End-Use (Land, Airborne, Naval), By Weapon Type (Missiles, Munitions, Guided Rockets, Guided Projectiles, Guided Firearms), By Component (Infrared, Laser, Global Positioning Systems (GPS), Radar) Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2020-2026

The smart weapons market is anticipated to witness significant growth over the coming time period owing to the increasing cross border conflicts and increasing FDI for manufacturing of weapons. Smart weapons usually utilize guidance systems that are ...

Publisher: Global Market Insights, Inc.
Chat with us